Athira Pharma

General Information


We are a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. With our product candidates, we aim to provide rapid cognitive improvement and alter the course of neurological diseases with our novel mechanism of action. Our approach is designed to augment neuronal growth factor signaling through HGF/MET, a naturally occurring regenerative system. We believe enhancing HGF/MET signaling has the potential to protect existing neurons from damage, reduce inflammation, promote regeneration, and positively modulate brain activity. We anticipate that all of these characteristics may improve neuronal health and translate into clinical benefits. Our pipeline is built from our proprietary drug discovery platform, or ATH platform, and consists of a series of small molecules that are designed to target either (1) the central nervous system, or CNS, by crossing the blood brain barrier, or BBB, or (2) the peripheral nervous system. Our lead candidate, ATH-1017, is a subcutaneous administered, BBB-penetrating, small molecule HGF/MET activator. In our Phase 1a and Phase 1b clinical trials, ATH-1017 for the treatment of Alzheimer’s disease, or AD, was well tolerated with no serious adverse events. These clinical trials recruited 88 subjects, including 11 subjects with mild-to-moderate AD. 

Employees: 15
Founded: 2011
Contact Information
Address 4000 Mason Road, Suite 300, Seattle, WA 98195, US
Phone Number (206) 221-8112
Web Address
View Prospectus: Athira Pharma
Financial Information
Market Cap $523.94mil
Revenues $0 mil (last 12 months)
Net Income $-6.3 mil (last 12 months)
IPO Profile
Symbol ATHA
Exchange NASDAQ
Shares (millions): 12.0
Price range $17.00 - $17.00
Est. $ Volume $204.0 mil
Manager / Joint Managers Goldman Sachs/ Jefferies / Stifel
CO-Managers JMP Securities
Expected To Trade: 9/18/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change